A B S T R A C T Purified acid-soluble and insoluble human collagen accelerated the clotting of plateletpoor plasma in silicone-treated tubes. The clotpromoting effect did not appear to be due to thromboplastic activity since the collagen preparations did not activate factor X in the presence of factor VII and calcium. Instead, collagen appeared to accelerate clotting by activating Hageman factor (factor XII) on the basis of the following findings: collagen increased the clot-promoting activity of partially purified Hageman factor but exerted no further effect in the presence of kaolin, a known activator of Hageman factor; clot-promoting eluates were obtained from collagen exposed to normal, hemophilic, or PTC-deficient plasma but not from collagen exposed to Hageman or PTA-deficient plasma. The collagen molecule itself appeared to be required for the clot-promoting activity since digestion with collagenase or thermal denaturation at pH 2.5 (about 350C) resulted in very marked reduction in clot-promoting activity. Since thermal denaturation is associated with transformation of collagen structure from triple helical to random coil form, it is suggested that the native form of collagen is essential for the ability to activate Hageman factor.
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Blockage of the free amino groups by treatment with nitrous acid or dinitrofluorobenzene only slightly reduced the clot-promoting activity of collagen. In contrast, since addition of cationic proteins to collagen markedly reduced pro-coagulant activity it is suggested that negatively charged sites on the collagen molecule are critical for Hageman factor activation. This suggestion is supported by INTRODUCTION The studies of several investigators have established that collagen causes platelet adherence and aggregation (1, 2) . In addition to effects on platelets it has been claimed that collagen initiates the clotting process by activating Hageman factor (factor XII) (3, 4) . One perplexing feature of these studies is the observation that increasing quantities of collagen lengthen the plasma clotting time (4) whereas all other Hageman activators shorten the plasma clotting time (5) . Ratnoff (5) reported contamination of some collagen preparations with tissue thromboplastin which may have been responsible for the postulated clot-promoting effect of collagen.
In view of the uncertainty concerning the mechanism of the effect of collagen on plasma coagulation this question was restudied with emphasis on the properties of the collagen which might be responsible for clot-promoting activity.
METHODS
Venous blood was drawn from normal subjects or patients with congenital coagulation factor deficiencies using disposable 20-gauge needles and polypropylene syringes (Roehr Products Co., Deland, Fla.). The blood was anticoagulated with 0.1 volume 4% trisodium citrate (Vita-rine Co., New York) and processed in polystyrene tubes (Kern Chemical Corp., Los Angeles, Calif.). The tubes were inverted and centrifuged at 2000 g for 20 min at 40C. The supernatant plasma was centrifuged two more times at 4VC for 10 min at 20,000 g. The resultant platelet-poor plasma containing less than 400 platelets/mm3 was used immediately or after storage in plastic tubes at -600C. All clotting tests were carried out in siliconetreated 10 X 75 mm glass tubes. Glassware and pipets were treated with silicone as previously described (6) .
All chemicals were reagent grade and were obtained from the following suppliers: Celite 512 from JohnsManville, New York; cytochrome c (equine heart, 3 times recrystallized) from Nutritional Biochemicals Corporation, Cleveland, Ohio; spermine and lysozyme from Calbiochem, Los Angeles, Calif.; protamine sulfate from Eli Lilly & Co., Indianapolis, Ind.; and methylene blue from J. T. Baker Chemical Co., N. Phillipsburg, N. J.
Glycine-HCl buffer, pH 2.5, 0.05 M, was made as described by Gomori (7) . Calcium chloride solutions and barbital-buffered saline (pH 7.4) were made as previously described (8) . Citrate-saline consisted of 5 volumes saline buffer mixed with 1 volume 4% trisodium citrate. Celite eluates were made from Celite 512 with normal plasma as previously described (9) .
Several collagen preparations were used: (a) Insoluble bovine collagen not dispersible in acid was obtained from Calbiochem (Lot 72281). The term 'insoluble collagen" is used to refer to this preparation. A similar preparation obtained from Sigma Chemical Co., St. Louis, Mo. (Lot 126B-210) was tested for tissue thromboplastic activity and found unsuitable for use in subsequent studies; see Table II. (b) Acid-soluble human fetal skin collagen (tropocollagen) was prepared from the skin of a stillborn infant by the method of Gallop and Seifter (10) . This preparation is referred to as "soluble collagen." (c) Acid-dispersible polymerized human adult skin collagen was extracted from cadaver skin by the Nishihara method as modified by Steven and Jackson (11, 29) . The term Nishihara collagen is used to refer to this preparation. 100 g corium, obtained by removing keratin and subcutaneous tissues with a scalpel, was minced with a scissors, washed in cold saline, and chopped in a meat grinder precooled with dry ice. The tissue was suspended in 500-1000 ml of cold 0.5 M sodium acetate solution, stirred constantly for 18 hr at 40C and deposited by centrifugation. The washing with sodium acetate was repeated five times. The tissue was then stirred constantly at room temperature (270) for 96 hr in 500 ml 0.22 AI NaH2PO4 buffer, pH 5.4, containing 5 g crude alpha amylase (Nutritional Biochemical Corporation) and 5 g NaCl. The tissue was then washed three times in cold distilled water and extracted three times wvith 500-ml aliquots of cold (40C) 1 Dinitrofluorobensene (DNFB)-treated collagen (14) . 100 mg Nishihara collagen was added to a flask containing 250 ml 5% aqueous NaHCOs solution and 500 ml of 1% (v/v) 2,4-dinitrofluorobenzene (Calbiochem) dissolved in 95% ethanol. After being stirred at room temperature (270) for 120 hr the collagen was deposited by centrifugation, washed three times with large volumes of distilled water, placed on a sintered glass suction filter, and extracted repeatedly with distilled water, followed by three extractions with ethanol and three extractions with acetone. The acetone-dried collagen was stored at -600 and suspended in buffered saline immediately before testing.
Acidified methantol-treated collagen (nmethanol collagen) (15) . 100 mg Nishihara collagen was added to 200 ml absolute methanol containing 1.5 ml concentrated HCl solution. The mixture was stirred constantly at room temperature (270) for 72 hr. The collagen was deposited by centrifugation, suspended in 50 ml cold distilled water, and dialyzed exhaustively against cold distilled water. The collagen was lyophylized, stored at -600, and suspended in buffered saline, pH 7.4, immediately before testing.
Deamination of collagen (16) . The entire procedure was carried out at room temperature (270C). 100 mg Nishihara collagen was suspended in 20 ml distilled water and stirred constantly for 18 hr. 10 g dry NaNO2 and then 50 ml glacial acetic acid were added. C02 gas was constantly bubbled through the reaction mixture to minimize oxidation of the nitrous acid and to provide agitation. After 24 hr an additional 10 g of NaNO2 and 50 ml glacial acetic acid was added to the mixture. After a further 24 hr the collagen was washed three times with 10% sodium chloride, transferred to a sintered glass suction filter, washed repeatedly with distilled water, and then dried with acetone.
Pepsin treatment of collagen (17) . Nishihara collagen was treated with pepsin (twice recrystallized, Worthington Biochemical Co.) as described by Rubin, Drake, Davison, Pfahl, Speakman, and Schmitt (17) . With minor modifications 10 mg collagen was dissolved in 5 ml glycine-HCl buffer (pH 2.5). 5 ml pepsin solution in glycine-HCl containing 0.2 mg pepsin/ml was added and the solution was stirred for 24 hr at room temperature (270).
The collagen-pepsin suspension was then dialyzed against cold barbital-buffered saline, pH 7.4, for 24 hr. The resultant dialyzed precipitate was redispersed in 7 ml glycine-HCl (pH 2.5), reprecipitated with dry KCI, deposited by centrifugation, and washed three times with 10-ml volumes of distilled water. The product was lyophilized and stored at -60'C.
Collagen eluates. 20 mg insoluble collagen was incubated with 1 ml platelet-poor plasma in a silicone-treated tube for 10 min at 370C. The collagen was deposited by centrifugation, washed six times with distilled water, and then eluted for 10 min at 370 with 2 ml 1.54 M sodium chloride, buffered with sodium barbital at pH 7.4. The eluate was dialyzed against saline buffer for 18 hr at 40 before being tested.
Hageman factor was purified as described by Ratnoff and Davie (18) . Using the definition proposed by these workers, that 1 U of Hageman factor is the amount of activity present in 1 ml of pooled normal human plasma, the preparation used had a specific activity of 10 and was free of other known clotting factor activities. Anti-activated PTA, an alpha globulin present in normal plasma, was prepared as described by Niemetz and Nossel (19) .
The clot-promoting activity of collagen was measured as follows: 0.1 ml collagen suspension was added to 0.1 ml platelet-poor plasma in a silicone-treated tube at 37°C. 0.1 ml cephalin (Thrombofax, Ortho Pharmaceutical Co., Raritan, N. J.) and 0.1 ml 0.025 M CaCl2 were added immediately or after incubating the collagen with the plasma for 5 or 10 min at 37°C. Five amounts (usually 100, 50, 25, 10, and 5 ,ug) of the control and test collagen preparations were tested and the clotting times plotted against collagen content on double logarithmic paper. Lines were drawn through the points obtained for each collagen preparation. The activity of the test collagen preparation was calculated as a percentage of that of the control collagen preparation.
Tissue thromboplastin test. A barium sulfate eluate of normal human serum containing factors VII and X was prepared as described by Biggs and Macfarlane (8) and concentrated so that factor VII and X activity was equal to that of a pool of 10 normal plasma samples. The eluate protein content was 6 mg/ml. 0.2 ml BaSO4 eluate, 0.4 ml saline, 0.2 ml 0.025 M CaC12, and the test addition were mixed and incubated for 5 min at 37°C. At intervals, 0.1 ml of this mixture was added to a clotting tube containing 0.1 ml factor X-deficient plasma (Diagnostic Reagents, Thame, Oxford, England) and 0.1 ml cephalin. 0.1 ml 0.025 M CaCl2 was added and the clotting time recorded. The tissue thromboplastin preparations tested were extracts of rabbit brain obtained from Difco Laboratories, Detroit, Michigan.
RESULTS
Incubation of purified collagen with normal plasma shortens the plasma clotting time (Fig. 1) . All collagen preparations produced qualitatively similar clot-promoting effects. The clot-promoting effect of the collagen preparation was greatly reduced by prior treatment with collagenase (Table I ).
The collagen preparations used failed to activate a preparation with factor VII and X activity in the presence of calcium, whereas crude connective tissue preparations, collagen obtained from Sigma Chemical Co. and tissue thromboplastin in amounts The tests were carried out in silicone-treated tubes. 0.1 ml addition in citrate-saline was added to 0.1 ml platelet-free plasma and after incubation at 370C 0.1 ml cephalin and 0.050 M CaCi2 were added and the clotting time was recorded. 100 ,ug collagen was added.
down to 8 X 1O-5 pg reacted with the factor VII and X preparation in clot-promoting reactions (Table II) .
To localize the site of action of collagen we investigated the effect of collagen on the clotting time of plasma samples lacking specific coagula- (Table IV) . The clot-promoting activity of the collagen eluate was destroyed by a purified anti-activated factor XI preparation. After 3 hr incubation with saline at 370C a collagen eluate caused normal plasma to clot in 126 The tests were carried out in silicone-treated tubes. Clotting mixtures consisted of: 0.1 ml plasma, 0.1 ml cephalin, and 0.1 ml kaolin (5 mg/ml) incubated at 370C (Table V) . Celite eluates replace factor XII and XI activity to a much greater extent than collagen eluates do but are free of factor IX activity (Table  V) . The clot-promoting activity of a purified Hageman factor preparation was markedly increased by kaolin, a substance known to activate Hageman factor (22) (23) (24) (25) , as well as by collagen (Fig. 2) . When purified Hageman factor was mixed with kaolin and collagen no further increase in clotpromoting activity occurred (Table VI) . This result is compatible with the thesis that the two materials affect the same stage of the clotting process. The physical and chemical properties of the collagen preparations responsible for their clot-promoting effect were next investigated. The effect of stepwise thermal denaturation at pH 2.5 of acidsoluble human fetal skin collagen is shown in Fig.  3 . There was a parallel reduction in relative viscosity and clot-promoting activity, both functions showing a sharp decline at about 35°. Addition to collagen of positively charged substances such as cytochrome c, lysozyme, protamine, or spermine prevented the formation of collagen eluate procoagulant activity as well as the clot-promoting effect of collagen on normal plasma. After 10 min incubation at 370, collagen shortened the clotting COLLAGEN (g) FIGURE 2 The effect of collagen on the clot-promoting activity of purified factor XII. Clotting time of a mixture of 0.1 ml Nishihara collagen, 0.1 ml factor XII, 0.1 ml factor XII-deficient plasma, incubated 5 min at 370C, 0.1 ml cephalin, and 0.1 ml CaCI2 0.025 M. The tests were carried out in silicone-treated tubes. The tests were carried out in silicone-treated tubes.
Clotting time of a mixture of 0.1 ml Hageman factor (3.5 ,sg/ml) or saline, 0.1 ml saline or collagen (100 Mg) or kaolin (10 mg/ml), 0.1 ml saline or collagen (100 jig), and 0.1 ml Hageman-deficient plasma incubated for 5 min at 370C and 0.1 ml cephalin and 0.1 ml CaCl2 0.025 M.
carboxyl groups by methanol treatment virtually abolished the coagulant activity of collagen whereas blockage of the epsilon amino groups with DNFB and blockage of the amino groups by deamination only slightly impaired the clot-promoting activity of collagen.
DIS CUS SION The results shown in Fig. 1 indicate that collagen accelerates the clotting of normal plateletfree plasma. The marked reduction of the coagulant effect by collagenase treatment provides evidence that the clot-promoting effect of the collagen preparations is due to the collagen molecule itself and not to a trace contaminant. This thesis is supported by the observation that parallel loss of viscosity and clot-promoting effect accompanied heating to 350C at acid pH since human collagen alters from the helical to a random coil conformation at about 36' (20) .
Very much smaller quantities of collagen pg) were used in this study than were reported by Niewiarowski to prolong the clotting time of plasma (10-50 mg) (4) . In the present investigation 5-20 mg of bovine tendon collagen preparations/ml of plasma also shortened clotting times. Selective adsorption of Hageman factor was not achieved with any of our preparations of collagen. The reason for the differences from Niewiarowski's findings is not clear. Possible explanations may involve differences in the physical state of the different collagen preparations (21) or impurities present in the collagen preparations.
The results of the experiments described in Table II indicate that the collagen preparations used in the present experiments contained no thromboplastic activity when tested by a method sensitive to 8 x 10-5 Pg amounts of thromboplastin and hence that the pro-coagulant activity of collagen was unlikely to be due to thromboplastin contamination.
The question then arises as to the site of action of collagen. The results recorded in Table III indicate that collagen greatly accelerated the clotting time of normal plasma or of plasma deficient in factor VIII or IX activity but had a lesser clotpromoting effect on plasma lacking factors XI or XII. In the presence of Celite, collagen produced little or no further acceleration of clotting. These results suggest that collagen affects the same stages of coagulation as Celite which, like kaolin and glass, has been shown to activate factors XII and XI (9, (22) (23) (24) (25) .
As recorded in Table IV , clot-promoting eluates were obtained from collagen exposed to normal plasma or plasma lacking factor VIII or IX activity but not from plasma lacking factor XI or XII activity. These results indicate that factors XII and XI are required for the formation of collagen eluate activity. A major part of the clotpromoting activity is probably activated factor XI since a purified anti-activated factor XI preparation destroyed the activity. As indicated by the results shown in Table V collagen eluate partially replaced factor XII and XI activity and not factor VIII activity, as do activated factor XI preparations. Collagen eluates made from normal or factor VIJI-deficient plasma also contained factor IX activity on repeated examination but eluates made from factor IX-deficient plasma did not accelerate the clotting of factor IX-deficient plasma. The amount of factor IX adsorbed was in the range of 0.5-4%o of the amount present in the plasma. Collagen did not, however, accelerate the activation of factor IX by an activated factor XI preparation when tested ih a previously described system for studying factor IX activation (30) .
The results are compatible with an action of collagen on Hageman factor. Further support for the idea that collagen activates Hageman factor is provided by the results of the experiments recorded in Fig. 2 which indicate that collagen increases the clot-promoting activity of purified Hageman factor. In the presence of kaolin, collagen exerted no further clot-promoting effect on purified Hageman factor (Table VI) . Had collagen and kaolin acted at different stages a further acceleration of clotting would have been expected. All the results are compatible with the thesis that collagen activates Hageman factor and thereby accelerates the clotting of plasma.
The remaining experiments were devoted to investigating the physical and chemical properties of the collagen molecule responsible for its ability to activate the Hageman factor. The reduction in viscosity of collagen solutions resulting from exposure to different temperatures is accompanied by transition of collagen from a triple helical to a random coil form (13, 26, 29) . The parallel reduction of viscosity and coagulant activity (Fig. 3) suggests that the native structure of collagen is necessary for its ability to activate Hageman factor. It is not clear why this should be so. Most other Hageman factor activators are insoluble and have sites of negative surface charge which, it has been suggested, are critical for adsorption and activation of the coagulation protein (6). Ratnoff and Crum (27) demonstrated Hageman factor activation by soluble ellagic acid. In studying congeners of ellagic acid these workers thought that rigidity of structure provided by lactone bridges was critical for the ability to activate Hageman factor. It might be postulated that the collagen helix provides a rigid setting for the binding sites and that attachment of the Hageman factor to the rigidly spaced binding sites results in conformational changes in the protein which manifest as biological activation. Alternative explanations for the inactivity of the random coil form have not been excluded. For example, it is possible that intra-or interchain neutralization of the polar groups might occur.
The neutralization of the coagulant activity of collagen by positively charged substances such as cytochrome is in keeping with the previous observations that positively charged substances neutralize Hageman factor activators (6) . Support for the suggestion that negatively charged sites are critical for Hageman factor adsorption and activation is provided by two positive and one negative set of results. Pepsin treatment of collagen removes the telopeptides which constitute lS by weight of the tropocollagen molecule but contain approximately twice the concentration of glutamic and aspartic acid residues as the parent molecule (17) . Such treatment reduces collagen coagulant activity by about 50%o. Esterification of collagen which neutralizes about 80-90% of the carboxyl groups (15, 28) almost completely abolishes Hageman factor activation. In contrast, blockage of the epsilon amino groups by DNFB treatment (14, 28) does not affect clot-promoting activity, and treatment of the collagen with nitrous acid which replaces all the free amino groups with hydroxyl groups and 20%o of the guanidyl groups with cyanamide groups causes only slight reduction in clot-promoting activity.
From the results of these experiments it is concluded that the free carboxyl groups of glutamic and aspartic acids are critical for the ability of collagen to activate Hageman factor. This conclusion supports the previous suggestion that negatively charged sites are critical for adsorption and activation of Hageman factor (6) .
